^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD1D expression

    i
    Other names: CD1D, CD1d Molecule, Antigen-Presenting Glycoprotein CD1d, CD1D Antigen, D Polypeptide, CD1d Antigen, R3G1, HMC Class I Antigen-Like Glycoprotein CD1D, Differentiation Antigen CD1-Alpha-3, T-Cell Surface Glycoprotein CD1d, Thymocyte Antigen CD1D, CD1A, R3
    Entrez ID:
    912
    Associations

    News

    Trials
    almost2years
    Role of Natural Killer T (NKT) Cells in Myeloma Biology and Therapy. (PubMed, Crit Rev Oncog)
    Chronic immune activation in this setting eventually sets the stage for malignancy, which can be targeted in both mouse models and GD patients by reducing the underlying antigen. NKT cells are thus integrally linked to MM pathogenesis and an attractive target for MM immunotherapy.
    Journal
    |
    CD1D (CD1d Molecule)
    |
    CD1D expression
    2years
    Genomic Analyses Unveil the Pathogenesis and Inform on Therapeutic Targeting in KMT2A-PTD AML (ASH 2023)
    Given the results obtained with menin inhibitors in KMT2A-rearranged and NPM1-mutated AML, our findings open an opportunity for exploiting a therapeutic vulnerability in all HOX-AML including KMT2A-PTD AML or AML with high MEN1 expression. Since HOX-AML highly express genes according to the HOX differentiation profile, stage-specific surface proteins coded by these genes would be promising targets.
    Genomic analysis
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • CD276 (CD276 Molecule) • SRSF2 (Serine and arginine rich splicing factor 2) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • PML (Promyelocytic Leukemia) • CD34 (CD34 molecule) • STAG2 (Stromal Antigen 2) • CD14 (CD14 Molecule) • LILRB4 (Leukocyte Immunoglobulin Like Receptor B4) • MEN1 (Menin 1) • CD1D (CD1d Molecule) • CD86 (CD86 Molecule) • HOXB2 (Homeobox B2) • NKX2-3 (NK2 Homeobox 3)
    |
    NPM1 mutation • TET2 mutation • KMT2A rearrangement • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • STAG2 mutation • MLL mutation • MLL translocation • KMT2A expression • KMT2A-PTD • CD1D expression
    2years
    Crosstalk within peripheral blood mononuclear cells mediates anti-inflammatory effects of n-3 PUFA-rich lipid emulsions in parenteral nutrition. (PubMed, Clin Nutr)
    These results show a mechanism for the beneficial effect of the n-3-rich Omegaven in patients with inflammatory conditions but questions its use in patients with cancer. Hence, our results may assist in choosing the best lipid emulsion for patients who require PN.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • CD14 (CD14 Molecule) • FOXP3 (Forkhead Box P3) • IL4 (Interleukin 4) • AVEN (Apoptosis And Caspase Activation Inhibitor) • CD1D (CD1d Molecule) • CD86 (CD86 Molecule)
    |
    IFNG expression • CD1D expression
    over2years
    Optimal, Off-the-Shelf, CAR-iNKT Cell Platform-Based Immunotherapy for Multiple Myeloma (ASH 2023)
    Finally, in ongoing xenograft assays, we find that compared to 106 28z BCMA CAR-iNKT and 5x106 untransduced iNKT, 5x106 28z BCMA CAR-iNKT cells maintain better disease control (p=0.008, day7). We conclude that CD28z by enhancing effector-target avidity and strength of IS constitutes the optimal CAR design for clinical development of CAR-iNKT therapy of multiple myeloma.
    IO biomarker
    |
    CD1D (CD1d Molecule)
    |
    CD1D expression
    over3years
    Lava-051, a Novel Bispecific Gamma-Delta T-Cell Engager (Gammabody), in Relapsed/Refractory MM and CLL: Pharmacodynamic and Early Clinical Data (ASH 2022)
    LAVA-051 has been well tolerated early in dose escalation with pharmacodynamics and early clinical signs reflective of its intended MoA. The differentiating importance of these pharmacodynamic parameters with any correlating preliminary antitumor activity will be further elucidated with continued dose escalation by the IV and SC route and in the determination of the RP2D and schedule.
    Clinical data • PK/PD data • IO biomarker
    |
    IL6 (Interleukin 6) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • CD1D (CD1d Molecule)
    |
    CD1D expression
    |
    LAVA-051
    almost4years
    Impact of epigenetic regulators on CD1d expression in Ewing’s sarcoma cell lines (CIMT 2022)
    Therefore, ES cell lines were treated with different epigenetic drugs (entinostat, tazemetostat, and gemcitabine) in stimulation experiments. Our data suggest that epigenetic regulators induce CD1d expression in ES cell lines. Further studies are needed whether the induction of CD1d expression in ES cells may enhance the cytotoxic efficiency of unconventional T cells, and therefore offers new treatment options for patients diagnosed with ES.
    Preclinical • IO biomarker
    |
    CD1D (CD1d Molecule)
    |
    CD1D expression
    |
    gemcitabine • Tazverik (tazemetostat) • Jingzhuda (entinostat)